A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: e27b682b9e2d846679ee9bc37ab9ed12a4d58187
First added on: Feb 10, 2025